Insider Selling: CRISPR Therapeutics AG (NASDAQ:CRSP) COO Sells $188,798.94 in Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) COO Julianne Bruno sold 3,366 shares of the business’s stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $56.09, for a total transaction of $188,798.94. Following the sale, the chief operating officer now directly owns 6,745 shares in the company, valued at approximately $378,327.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

CRISPR Therapeutics Trading Up 1.2 %

Shares of NASDAQ:CRSP opened at $56.63 on Thursday. The firm has a market cap of $4.81 billion, a price-to-earnings ratio of -20.82 and a beta of 1.78. The stock’s 50-day moving average price is $56.76 and its two-hundred day moving average price is $64.57. CRISPR Therapeutics AG has a 12-month low of $37.55 and a 12-month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Wednesday, May 8th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The company had revenue of $0.50 million for the quarter, compared to analyst estimates of $25.53 million. During the same quarter in the previous year, the company earned ($0.67) earnings per share. The business’s revenue was down 99.5% on a year-over-year basis. As a group, research analysts forecast that CRISPR Therapeutics AG will post -5.51 earnings per share for the current fiscal year.

Institutional Trading of CRISPR Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Riggs Asset Managment Co. Inc. grew its position in CRISPR Therapeutics by 66.7% during the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after acquiring an additional 200 shares during the period. Orion Capital Management LLC increased its position in CRISPR Therapeutics by 44.0% during the 1st quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock worth $49,000 after purchasing an additional 220 shares in the last quarter. Itau Unibanco Holding S.A. raised its holdings in CRISPR Therapeutics by 10.8% in the third quarter. Itau Unibanco Holding S.A. now owns 2,521 shares of the company’s stock valued at $114,000 after buying an additional 245 shares during the period. WealthPlan Investment Management LLC lifted its position in CRISPR Therapeutics by 3.1% during the fourth quarter. WealthPlan Investment Management LLC now owns 9,663 shares of the company’s stock valued at $605,000 after buying an additional 288 shares in the last quarter. Finally, Merlin Capital Inc grew its stake in CRISPR Therapeutics by 3.3% during the third quarter. Merlin Capital Inc now owns 9,092 shares of the company’s stock worth $413,000 after buying an additional 290 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently weighed in on CRSP. Wells Fargo & Company lowered their price target on CRISPR Therapeutics from $70.00 to $65.00 and set an “equal weight” rating on the stock in a report on Thursday, May 9th. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, May 9th. Citigroup decreased their price objective on shares of CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating on the stock in a research report on Thursday, May 23rd. Barclays lowered their price objective on shares of CRISPR Therapeutics from $80.00 to $67.00 and set an “equal weight” rating on the stock in a research note on Thursday, May 9th. Finally, Needham & Company LLC restated a “buy” rating and set a $88.00 target price on shares of CRISPR Therapeutics in a research report on Monday, June 17th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $75.71.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.